Atyr Pharma Inc
LIFE - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.16B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.16 Billion |
|---|---|
| Enterprise Value | $2.12 Billion |
| Earnings per Share | $1.14 |
| Beta | 4.52 |
| Outstanding Shares | 64,396,000 |
Return
| Return on Equity | -157.80% |
|---|---|
| Return on Assets | -89.16% |
| Return on Invested Capital | -128.98% |
Valuation & Multiples
| P/E Ratio | -11.89 |
|---|---|
| PEG | 40.9 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -37.98 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS
$0.49
Est. $0.08Revenue
$235.22 M
Est. $169.05 MNext Earnings Call
Expected Date
December 2, 2026
EPS Estimate
$0.06
Consensus analyst estimateRevenue Estimate
$125.55 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 33.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.48%▼ 59.02% |
|---|---|
| Total Invested | $478,060▼ 97.95% |
| Investors Holding | 14▼ 85.00% |
About Atyr Pharma Inc
80 employees
CEO: Sanjay Shukla
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological ...